Insys stock: buy or sell?
May 21st, 2019
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.
Should I buy Insys stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Insys stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Insys Therapeutics stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 2 ratings published for INSY stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-8||Royal Bank of Canada||Outperform||Outperform|
Insys stock analysis
Insys Therapeutics shares plunged -5.21% to $0.91 today.
Insys Therapeutics ended today at $0.91 and plunged a scary -5.21%. INSY marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $4.37 would break this short term down trend and open possibilities for reversing this situation.
Shares of Insys Therapeutics plummed a dreadful -14.15% this week. This was the fourth red week in a row, sliding in full a -81.95%.
Far behind is the all-time high Insys recorded late August 2018 and since then the price is -92.19% below that top. Since early April, when INSY stock price broke down the 20-weeks moving avarage line, it slid $-3.92 per share (-81.16%).
Insys stock price history
Insys stock went public on November 2nd, 2017 with a price of $4.791. Since then, INSY stock lost a -81.00%, with a yearly average of -81.00%.
1: Adjusted price after possible price splits or reverse-splits.
Insys stock historical price chart
INSY stock reached all-time highs on August with a price of $11.65.
Insys stock price target is $7.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price prediction for Insys stock was published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-8||Royal Bank of Canada||Lowers Target||$9.00||$7.00||-22.2%|
Financials and fundamental analysis
Earnings date and Earnings per ShareInsys Therapeutics reported great results for 2018-Q4 on March. Insys jumped Earnings per Share (EPS) by 18.20%, beating experts consensus of $-0.33. Insys posted $-0.39.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Insys Therapeutics annual turnover plunged a scary -41.66% to $82.08 million dollars from $140.69 marked in 2017. In contrast, its profit margin (compared to revenues) jumped to -151.69%, that is $-124.51 million.
|2013||$99 M||-||$40 M40.7%||-|
|2014||$222 M||123.71%||$38 M17.1%||-5.95%|
|2015||$331 M||48.92%||$58 M17.7%||53.98%|
|2016||$242 M||-26.76%||$7.59 M3.1%||-87.02%|
|2017||$141 M||-41.93%||$-226.84 M-161.2%||-3,088.60%|
|2018||$82 M||-41.66%||$-124.51 M-151.7%||-45.11%|
Quarterly financial resultsInsys Therapeutics posted $16.36 M in revenues for 2018-Q4, a -10.84% decline compared to previous quarter. Reported quarter earnings marked $-46.29 million with a profit margin of -283.02%. Profit margin collapsed a -116.80% compared to previous quarter when profit margin was -166.22%. When comparing sales to same quarter last year, Insys sales marked a frightening slide and collapsed a -48.05%. Looking back to recent quarterly results, Insys Therapeutics posted 4 positive quarters in a row.
|2017-Q1||$36 M||-||$-6.52 M-18.1%||-|
|2017-Q2||$43 M||18.41%||$-8.18 M-19.2%||25.46%|
|2017-Q3||$31 M||-27.97%||$-166.32 M-542.3%||1,933.25%|
|2017-Q4||$31 M||2.66%||$-47.11 M-149.6%||-71.68%|
|2018-Q1||$24 M||-24.06%||$-20.37 M-85.2%||-56.76%|
|2018-Q2||$23 M||-1.86%||$-27.35 M-116.6%||34.27%|
|2018-Q3||$18 M||-21.82%||$-30.49 M-166.2%||11.50%|
|2018-Q4||$16 M||-10.84%||$-46.29 M-283.0%||51.81%|
Insys ownershipWhen you are planning to invest in a stock, it's always worth to have a look its ownership structure.
Insys shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 63.69% of all shares.
In case of Insys stock, 24.38% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for INSY stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Insys Therapeutics:
|Market cap||$67.7 M||$225.7 M||$395.0 M||$5.7 B||$1.5 B|
|Total shares||74.4 M||78.9 M||87.4 M||30.7 M||79.2 M|
|Float shares||27.1 M||77.7 M||59.9 M||29.8 M||66.0 M|
|- Institutional holdings (%)||24.4%||19.7%||58.8%||82.0%||117.6%|
|- Insider holdings (%)||63.7%||11.6%||6.0%||0.6%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$0.91 - $1.00|
|Average true range||$0.43|
|50d mov avg||$3.99|
|100d mov avg||$4.35|
|200d mov avg||$5.98|
Insys performanceTo measure stock performance is always good to benchmark with competitors or related stocks. In the following table, we compare Insys performance to AcelRx Pharmaceuticals, BioDelivery Sciences International, GW Pharmaceuticals, Heron Therapeutics, Merck, Mylan and Recro Pharma: